317 related articles for article (PubMed ID: 33661486)
1. Secukinumab: A Review in Psoriatic Arthritis.
Blair HA
Drugs; 2021 Mar; 81(4):483-494. PubMed ID: 33661486
[TBL] [Abstract][Full Text] [Related]
2. Secukinumab: A Review in Psoriatic Arthritis.
Shirley M; Scott LJ
Drugs; 2016 Jul; 76(11):1135-45. PubMed ID: 27299434
[TBL] [Abstract][Full Text] [Related]
3. Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study.
Coates LC; Gladman DD; Nash P; FitzGerald O; Kavanaugh A; Kvien TK; Gossec L; Strand V; Rasouliyan L; Pricop L; Ding K; Jugl SM; Gaillez C;
Arthritis Res Ther; 2018 Dec; 20(1):272. PubMed ID: 30526678
[TBL] [Abstract][Full Text] [Related]
4. Secukinumab Efficacy on Psoriatic Arthritis GRAPPA-OMERACT Core Domains in Patients with or Without Prior Tumor Necrosis Factor Inhibitor Use: Pooled Analysis of Four Phase 3 Studies.
Orbai AM; Husni ME; Gladman DD; Leung YY; Siebert S; Tillett W; Vis M; Chambenoit O; Meng X; Mease PJ
Rheumatol Ther; 2021 Sep; 8(3):1223-1240. PubMed ID: 34218429
[TBL] [Abstract][Full Text] [Related]
5. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.
McInnes IB; Behrens F; Mease PJ; Kavanaugh A; Ritchlin C; Nash P; Masmitja JG; Goupille P; Korotaeva T; Gottlieb AB; Martin R; Ding K; Pellet P; Mpofu S; Pricop L;
Lancet; 2020 May; 395(10235):1496-1505. PubMed ID: 32386593
[TBL] [Abstract][Full Text] [Related]
6. Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis.
Lindström U; Glintborg B; Di Giuseppe D; Schjødt Jørgensen T; Gudbjornsson B; Lederballe Grøn K; Aarrestad Provan S; Michelsen B; Lund Hetland M; Wallman JK; Nordström D; Trokovic N; Love TJ; Krogh NS; Askling J; Jacobsson LTH; Kristensen LE
Rheumatology (Oxford); 2021 Aug; 60(8):3635-3645. PubMed ID: 33367900
[TBL] [Abstract][Full Text] [Related]
7. Association of previous treatment with anti-tumour necrosis factor inhibitors with the effectiveness of secukinumab in the treatment of psoriatic arthritis: systematic review and meta-analysis.
Xu Y; Li Y; Dong M; Gao Z; Chen X; Liu H; Shen M
Rheumatology (Oxford); 2020 Dec; 59(12):3657-3665. PubMed ID: 33038239
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study.
Kavanaugh A; McInnes IB; Mease PJ; Hall S; Chinoy H; Kivitz AJ; Wang Z; Mpofu S
J Rheumatol; 2016 Sep; 43(9):1713-7. PubMed ID: 27307536
[TBL] [Abstract][Full Text] [Related]
9. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study.
Mease P; van der Heijde D; Landewé R; Mpofu S; Rahman P; Tahir H; Singhal A; Boettcher E; Navarra S; Meiser K; Readie A; Pricop L; Abrams K
Ann Rheum Dis; 2018 Jun; 77(6):890-897. PubMed ID: 29550766
[TBL] [Abstract][Full Text] [Related]
10. Secukinumab retention rate is greater in patients with psoriatic arthritis presenting with axial involvement.
Adami G; Idolazzi L; Benini C; Fracassi E; Carletto A; Viapiana O; Gatti D; Rossini M; Fassio A
Reumatismo; 2023 May; 75(1):. PubMed ID: 37154254
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Psoriatic Arthritis: An Argentinean Perspective.
Aiello E; Bianculli PM; Bhattacharyya D; Gunda P; Citera G
Value Health Reg Issues; 2019 Dec; 20():86-94. PubMed ID: 31103950
[TBL] [Abstract][Full Text] [Related]
12. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial.
Baraliakos X; Gossec L; Pournara E; Jeka S; Mera-Varela A; D'Angelo S; Schulz B; Rissler M; Nagar K; Perella C; Coates LC
Ann Rheum Dis; 2021 May; 80(5):582-590. PubMed ID: 33334727
[TBL] [Abstract][Full Text] [Related]
13. Secukinumab real world drug retention compared to TNF-alpha inhibitors in psoriatic arthritis.
Eviatar T; Zisman D; Gendelman O; Reitblat T; Balbir-Gurman A; Mashiach T; Almog R; Elkayam O
Clin Exp Rheumatol; 2022 Jan; 40(1):15-23. PubMed ID: 33427613
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data.
Deodhar A; Mease PJ; McInnes IB; Baraliakos X; Reich K; Blauvelt A; Leonardi C; Porter B; Das Gupta A; Widmer A; Pricop L; Fox T
Arthritis Res Ther; 2019 May; 21(1):111. PubMed ID: 31046809
[TBL] [Abstract][Full Text] [Related]
15. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study.
McInnes IB; Mease PJ; Ritchlin CT; Rahman P; Gottlieb AB; Kirkham B; Kajekar R; Delicha EM; Pricop L; Mpofu S
Rheumatology (Oxford); 2017 Nov; 56(11):1993-2003. PubMed ID: 28968735
[TBL] [Abstract][Full Text] [Related]
16. Secukinumab: A Review in Ankylosing Spondylitis.
Blair HA
Drugs; 2019 Mar; 79(4):433-443. PubMed ID: 30793255
[TBL] [Abstract][Full Text] [Related]
17. Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies.
Coates LC; Wallman JK; McGonagle D; Schett GA; McInnes IB; Mease PJ; Rasouliyan L; Quebe-Fehling E; Asquith DL; Fasth AER; Pricop L; Gaillez C
Arthritis Res Ther; 2019 Dec; 21(1):266. PubMed ID: 31801620
[TBL] [Abstract][Full Text] [Related]
18. Secukinumab for rheumatology: development and its potential place in therapy.
Koenders MI; van den Berg WB
Drug Des Devel Ther; 2016; 10():2069-80. PubMed ID: 27445458
[TBL] [Abstract][Full Text] [Related]
19. Subacute thyroiditis in a patient with psoriatic arthritis switched from secukinumab to adalimumab: a case report and literature review.
Nakagawa J; Fujikawa K; Akagi M; Nakaji K; Yasui J; Hanatani Y; Hara T; Mizokami A; Kawakami A
Mod Rheumatol Case Rep; 2021 Jan; 5(1):36-39. PubMed ID: 32731788
[TBL] [Abstract][Full Text] [Related]
20. Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK.
Buchanan V; Sullivan W; Graham C; Miles L; Jugl SM; Gunda P; Halliday A; Kirkham B
Pharmacoeconomics; 2018 Jul; 36(7):867-878. PubMed ID: 29797187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
